TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03572010

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: FeFum fortified maize test meal
Description: Maize porridge extrinsically labeled with 2 mg ferrous fumarate (58FeFum); only for iron deficient children (defined by plasma ferritin \<40 mikrogramm/L and/or sTfR \>8.3 mg/L); cereal staple foods, like maize, depending on milling, may be high in phytic acid, a potent iron absorption inhibitor

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: FeSO4 fortified LNS
Description: self-made Lipid-based nutritional supplement (LNS) extrinsically fortified and labeled with 6 mg ferrous sulfate (57FeSO4); only for iron deficient children (defined by plasma ferritin \<40 mikrogramm/L and/or sTfR \>8.3 mg/L); LNS may be a better food matrix for iron supplementation compared to maize-based porridge; contains canola oil, peanut paste, milk powder, sugar, maltodextrin and palm stearin

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: FeSO4 supplement
Description: 170 mg iron tablets as FeSO4 (containing 55 mg of elemental iron) with 6 mg extrinsically labeled 57Fe; will be given together with a glass of water; only for iron deficient children (defined by plasma ferritin \<40 mikrogramm/L and/or sTfR \>8.3 mg/L);

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: FeSO4 fortified fruit juice
Description: Fruit juice labeled with 12 mg 57Fe as FeSO4; in the group for iron sufficient children
Study: NCT03962816

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20 µg recombinant hepatitis B vaccine at months 0, 1, 2, and 6
Description: four-dose, 20 µg per dose
Study: NCT03625323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eftilagimod alpha
Description: APC activator, MHC II agonist, LAG-3 fusion protein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eftilagimod alpha
Description: APC activator, MHC II agonist, LAG-3 fusion protein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eftilagimod alpha
Description: APC activator, MHC II agonist, LAG-3 fusion protein
Study: NCT03962816

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 60 µg recombinant hepatitis B vaccine at months 0, 1, 2, and 6
Description: four-dose, 60 µg per dose
Study: NCT01783015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Etanercept 50 mg once-weekly
Study: NCT03625323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab (KEYTRUDA®)
Description: anti-PD-1 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab (KEYTRUDA®)
Description: anti-PD-1 antibody
Study: NCT02342535

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Physical Activity
Description: Culturally tailored physical activity intervention for South Asian women and their children.
Study: NCT00818558

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISET Methode
Description: Sampling of blood - ISET Methode

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISET Methode
Description: Sampling of blood - ISET Methode

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISET Methode
Description: Sampling of blood - ISET Methode

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISET Methode
Description: Sampling of blood - ISET Methode

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISET Methode
Description: Sampling of blood - ISET Methode

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISET Methode
Description: Sampling of blood - ISET Methode
Study: NCT01515891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: 90 µCi (3.33 MBq) \[14C\]-labeled of 100 mg BIA 9-1067 (single-dose).
Study: NCT02942823

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The serious game KOP
Description: The serious game transfers knowledge about nutrition (food pyramid, energy density of foods, which foods contribute to satiety and which not, energy in liquids, self-reflexive diagnostic tool to analyze daily food intake), physical activity (a motion-control to navigate through the game is partly used, relationship between energy expenditure and energy intake) and psychological aspects (relaxation-exercises, what is stress, stress-coping strategies).
Study: NCT01783015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Etanercept 50 mg once-weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Etanercept placebo once-weekly
Study: NCT04349553

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: ZH9PA and ZH9
Description: 150mL vaccine for oral administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZH9PA and ZH9
Description: 150mL vaccine for oral administration

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 150mL vaccine for oral administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 150mL vaccine for oral administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 150mL vaccine for oral administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 150mL vaccine for oral administration

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: ZH9PA
Description: 150mL vaccine for oral administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZH9PA
Description: 150mL vaccine for oral administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZH9PA
Description: 150mL vaccine for oral administration
Study: NCT04089553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4635
Description: In Module 1, participants will receive AZD4635 75 mg capsule orally QD for first 14 days and thereafter will continue to receive 75 mg orally QD Q4W.~In Module 2, participants will receive AZD4635 50 mg / 75 mg capsule orally QD Q2W of 28-day cycle for the first 4 doses and Q4W thereafter.~In both modules, participants will receive treatment until will derive clinical benefit as judged by the investigator or until confirmed disease progression, unacceptable toxicity, started alternative anticancer therapy, withdrawal of consent, or lost to-follow-up, whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4635
Description: In Module 1, participants will receive AZD4635 75 mg capsule orally QD for first 14 days and thereafter will continue to receive 75 mg orally QD Q4W.~In Module 2, participants will receive AZD4635 50 mg / 75 mg capsule orally QD Q2W of 28-day cycle for the first 4 doses and Q4W thereafter.~In both modules, participants will receive treatment until will derive clinical benefit as judged by the investigator or until confirmed disease progression, unacceptable toxicity, started alternative anticancer therapy, withdrawal of consent, or lost to-follow-up, whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleclumab
Description: In Module 2, participants will receive oleclumab 1500 mg IV (solution for infusion after dilution, 50 mg/mL) Q2W of 28-day cycle for the first 4 doses and Q4W thereafter until will derive clinical benefit as judged by the investigator or until confirmed disease progression, unacceptable toxicity, started alternative anticancer therapy, withdrawal of consent, or lost to-follow-up, whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: In Module 1 after monotherapy of AZD4635, participants will receive durvalumab 1500 mg IV (solution for infusion after dilution, 50 mg/mL) Q4W until will derive clinical benefit as judged by the investigator or until confirmed disease progression, unacceptable toxicity, started alternative anticancer therapy, withdrawal of consent, or lost to-follow-up, whichever occurs first.
Study: NCT03219853

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: selenium enriched parsnips
Description: Parsnips which have been grown in a selenium enriched environment

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: selenium enriched parsnips
Description: Parsnips which have been grown in a selenium enriched environment

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Conventional parsnips
Description: Parsnips which have been grown in a conventional environment

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Conventional parsnips
Description: Parsnips which have been grown in a conventional environment
Study: NCT02647463

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attachment and Biobehavioral Catch-up (ABC)
Study: NCT03259139

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Video games and violence
Description: Participants will be randomly assigned to play a video game which contains either (1) no violent content, (2) violent content with swords, or (3) violent content with guns. The game, rated E, is age appropriate and modded to include guns in the appropriate condition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video games and violence
Description: Participants will be randomly assigned to play a video game which contains either (1) no violent content, (2) violent content with swords, or (3) violent content with guns. The game, rated E, is age appropriate and modded to include guns in the appropriate condition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video games and violence
Description: Participants will be randomly assigned to play a video game which contains either (1) no violent content, (2) violent content with swords, or (3) violent content with guns. The game, rated E, is age appropriate and modded to include guns in the appropriate condition.
Study: NCT04057287

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT03625323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab (KEYTRUDA®)
Description: anti-PD-1 antibody
Study: NCT01783015

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Etanercept placebo once-weekly
Study: NCT02927314

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CF102
Description: orally q12h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CF102
Description: orally q12h

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: orally q12h
Study: NCT02834897

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: EOS and CT Exam
Description: EOS and CT Examen for pregnant women in the 8th month of pregnancy
Study: NCT01433874

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary recruitment maneuver
Description: A pulmonary recruitment maneuver consisting of five manual pulmonary inflations was performed with a maximum pressure of 60 cmH2O. The anesthesiologist held the fifth positive pressure inflation for approximately 5 seconds.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraperitoneal normal saline infusion
Description: The upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500cc. We will leave the fluid in the abdominal cavity

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: combined group
Description: The upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500cc. Later, a pulmonary recruitment maneuver consisting of five manual pulmonary inflations was performed with a maximum pressure oof 60 cmH2O.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Co2 was removed by passive exsufflation through the port site.
Study: NCT04293965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single ascending dose of X842
Description: A total of 7 dose groups will be set for the ascending dose: 5.6 mg, 12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg, 225 mg. In the 5.6 mg dose group, 4 subjects will receive X842; in the 12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg, 225 mg dose groups, 8 subjects in each group will receive X842. Each subject can only receive a certain dose level and cannot enter in multiple dose groups repeatedly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple ascending dose of X842
Description: Two dose groups will be set, including the groups receiving the recommended phase II dose and a higher dose; Eight subjects will be enrolled in each group, with half male and half female, who will receive X842 once daily for 5 consecutive days. Each subject can only receive a certain dose level and cannot enter in multiple dose groups repeatedly.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food Effect
Description: Twelve subjects (appropriate ratio of male to female) screened for eligibility will be randomized into Group A and B. The 6 subjects in Group A will take the study drug (X842) in fasted condition and subject in Group B will take the study drug in fed condition in the 1st cycle. In the 2nd Cycle, subjects in Group A will take the study drug in fed condition, and subjects in Group B will take the study drug in fasted condition. The interval between the two cycles is at least 7 days.
Study: NCT01439334

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MB-SBIRT (multiple behavior screening, brief intervention and referral to treatment) Online Program Brief
Description: Online prevention program using positive images

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MB-SBIRT (multiple behavior screening, brief intervention and referral to treatment) Online Program Extended Length
Description: Online Program Extended Length

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MB-SBIRT (multiple behavior screening, brief intervention and referral to treatment) Control
Description: Control
Study: NCT02920554

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: wedge resection
Description: The extent of hepatic resection is wedge resection of liver including gallbladder fossa
Study: NCT00466752

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: microarray analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies
Study: NCT02920554

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bisegmentectomy
Description: The extent of hepatic resection is 4b/5 bisegmentectomy of liver
Study: NCT00466752

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: needle biopsy
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: needle biopsy
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo prostatectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo prostatectomy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: western blotting
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: western blotting
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RNA analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RNA analysis
Description: Correlative studies
Study: NCT01593748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine and Pazopanib
Description: Gemcitabine 1000 mg/m2 by IV on day 1 and day 8 of a 21 day cycle. Pazopanib 800 mg by oral tablet daily for a 21 day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine and Docetaxel
Description: Gemcitabine 900 mg/m2 by IV on day 1 and day 8 of a 21 day cycle. Docetaxel 100 mg/m2 by IV on day 8 of a 21 day cycle.
Study: NCT04364217

Intervention type: DEVICE
Group type: OTHER
Intervention: Luminis ultrapulse fractional ablative carbon dioxide laser
Description: This laser will target water molecules and ablate columns of tissue that are approximately 3mm deep.
Study: NCT04509089

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Suremedix Device
Description: Performing measurements using the Suremedix Device by applying gradually ascending air pressure to the subject lungs through a mouse piece while measuring respiratory chest motion, PPG and ECG.
Study: NCT04230850

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Static Cupping
Description: Two cups will be applied unilaterally to the lumbar paraspinals. The skin will be elevated to 1.5 cm ensuring standardized pressure. Cups will remain on the treatment area statically for 4 minutes prior to removal. Another 4 minute bout of identical treatment to the contralateral side will follow. (Participants will be equally dispersed into three treatment groups via stratified randomization).
Study: NCT04205825

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The New Safety Checklist
Description: Patients randomized in the New Safety Checklist intervention, nurses will use the New Safety Checklist, which we have named: INCARDIO-PASS (Interventional CARDIOlogy-Patient Safety System) checklist.
Study: NCT04057287

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT02266095

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oval-8 Splint
Description: Splinting with Oval-8

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tee Pee Splint
Description: Splinting with Tee Pee

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Forearm Based Splint
Description: Splinting with Forearm based
Study: NCT01770730

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Urine LAM strip test
Description: This is a point-of-care lateral flow strip test to detect the presence of lipoarabinomannan (LAM) in patient urine samples. Only patients with a grade 2-5 visual band intensity will be considered positive and commenced on treatment
Study: NCT01259882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05089771
Description: Subjects will receive single ascending doses of PF-05089771 or placebo to investigate the safety/tolerability and PK of PF-05089771. The PK of alternative formulations of PF-05089771 and the effect of food on PK may also be investigated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05089771
Description: Subjects will receive single ascending doses of PF-05089771 or placebo to investigate the safety/tolerability and PK of PF-05089771. The PK of alternative formulations of PF-05089771 and the effect of food on PK may also be investigated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05089771
Description: Subjects will receive single doses of PF-05089771 or placebo in a fully randomized crossover design. The investigation of the safety/tolerability and PK of PF-05089771 will occur. In addition the exploratory pharmacodynamics of PF-05089771 will be investigated using novel biomarkers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05089771
Description: Subjects will receive single doses of PF-05089771 or placebo in a fully randomized crossover design. The investigation of the safety/tolerability and PK of PF-05089771 will occur.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05089771
Description: Subjects will receive single doses of PF-05089771 or placebo in a fully randomized crossover design. The investigation of the safety/tolerability and PK of PF-05089771 will occur.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05089771
Description: Subjects will receive single doses of PF-05089771 or placebo in a fully randomized crossover design. The investigation of the safety/tolerability and PK of PF-05089771 will occur.
Study: NCT01795755

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mentalization based inpatient treatment.
Description: 1-3 month of inpatient treatment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mentalization based inpatient treatment.
Description: 1-3 month of inpatient treatment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Horse assisted Therapy (HAT)
Description: A structured program of 12 X 90 minute HAT sessions (horse care, ground and mounted work) conducted by two clinically qualified therapists who are also Level I Riding Instructors.
Study: NCT03055078

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cells
Description: Patients in the cell treated group were given umbilical cord derived mesenchymal stem cells by intravenous infusion besides conventional therapy. There was only conventional treatment in the control group. All patients after treatment for 1months, 3months, 6months and 9months were evaluated respectively the therapeutic effect.
Study: NCT03112187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Supplement
Description: Ferfer® is a multi-ingredient supplement containing micro-encapsulated iron pyrophosphate (to form liposomes), vitamin C and vitamin B12 which are valuable for the control of nutritional deficiencies or increased organic needs of iron.
Study: NCT03641560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide was administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT)
Description: All participants were required to maintain ADT during study treatment, either using a Gonadotropin Releasing Hormone (GnRH) agonist/antagonist or having a history of bilateral orchiectomy